Health Care SPDR (ETF) Just Recorded A Sigfniciant Bearish Options Activity

 Health Care SPDR (ETF) Just Recorded A Sigfniciant Bearish Options Activity

In today’s session Health Care SPDR (ETF) (XLV) recorded an unusually high (3,052) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious XLV decrease. With 3,052 contracts traded and 63254 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: XLV161216P00067000 closed last at: $0.46 or 35.3% up. Health Care SPDR (ETF) (NYSEARCA:XLV) has declined 2.21% since April 29, 2016 and is downtrending. It has underperformed by 8.30% the S&P500.

Health Care Select Sector SPDR Fund seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The ETF has a market cap of $13.38 billion. The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor’s 500 Composite Stock Index (S&P 500). It has a 5.3 P/E ratio. The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology.

XLV Company Profile

Health Care Select Sector SPDR Fund (the Fund) seeks to provide investment results that correspond to the price and yield performance of the Health Care Select Sector of the S&P 500 Index (the Index). The Index includes companies whose primary business may include healthcare equipment and supplies, healthcare services, biotechnology and pharmaceuticals.

Another recent and important Health Care SPDR (ETF) (NYSEARCA:XLV) news was published by which published an article titled: “Valuation Dashboard: Healthcare – Update” on November 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment